BCAL Diagnostics Limited (AU:BDX) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BCAL Diagnostics Limited is making significant strides in breast cancer diagnostics, having raised $10.5 million through an oversubscribed placement to fund the commercialization of its innovative blood test. The company has nearly completed its SENSIBLE-3 study, commenced the BREASTEST clinical validation study, and invested in advanced laboratory equipment, increasing its testing capacity. These developments highlight BCAL’s commitment to enhancing diagnostic efficiency and accuracy for breast cancer patients.
For further insights into AU:BDX stock, check out TipRanks’ Stock Analysis page.